Post-market surveillance evaluation of authorized generic drug products (U01)
The purpose of this study is to evaluate existing tools and to develop new methods to monitor the drug safety, efficacy, usage, and substitution patterns of model authorized generics in different therapeutic categories in comparison with those of brand name drugs and other generic drugs. The outcome of this study will help determine whether any potential bias against generic drugs is involved in generic drug complaints and affects generic substitution.
General information about this opportunity
Last Known Status
Deleted 07/21/2014 (Archived.)
Program Number
RFA-FD-14-013 Federal Agency/Office
Agency: Department of Health and Human ServicesOffice: Food and Drug Administration
Type(s) of Assistance Offered
Cooperative Agreement Number of Awards Available
2 Who is eligible to apply/benefit from this assistance?
Applicant Eligibility
FOREIGN INSTITUTIONS ARE ELIGIBLE TO APPLY What is the process for applying and being award this assistance?
Deadlines
06/21/2014 Other Assistance Considerations
Formula and Matching Requirements
This program does not have cost sharing or matching requirements. Who do I contact about this opportunity?
Headquarters Office
Martin BernardGrants Management Specialist
Phone 240-402-7564
Website Address
http://grants.nih.gov/grants/guide/rfa-files/RFA-FD-14-013.html
E-mail Address
Martin.Bernard@fda.hhs.gov
Financial Information
Obligations
$400,000.00 Range and Average of Financial Assistance
Awards range from $350,000.00 to $400,000.00
